Dana-Farber Cancer Institute has a longstanding commitment to patient safety by ensuring high quality cellular therapy (CT) programs. As part of this commitment, there are several Quality Assurance teams, and each is charged with ensuring program success from a specific perspective: donor related, product related, and clinical treatment related. The combined efforts of these teams ensure quality and ongoing compliance to the highest of standards for cellular therapy programs.
In keeping with those industry standards, our CTQA teams maintain independent reporting structures. This means that, because of independent reporting, everything we do is transparent and intended to ensure the very best cellular therapy services, products, and clinical trials for patients.
About the Cellular Therapy Quality Assurance (CTQA) Teams
The Cellular Therapies Quality Assurance teams are a central resource for clinicians, researchers, and other staff — both at Dana-Farber and across all of our Harvard affiliates — for:
Quality Assurance and Regulatory Compliance
- Performing internal and external audits to ensure that Dana-Farber and its contracted services and suppliers operate in compliance with established policies, procedures and standards
- Auditing departmental practices and instituting corrective action when needed
- Ensuring that Dana-Farber is always in a state of inspection readiness and compliance with all policies and regulations
